What is the recommended dosage of letrozole (2.5 mg) or anastrozole (1 mg) to increase final height in pubertal boys with short stature?

Letrozole and Anastrozole Are NOT Recommended for Height Augmentation in Pubertal Boys

Neither letrozole nor anastrozole should be used for height augmentation in pubertal boys with short stature, as these medications are not FDA-approved for this indication, lack sufficient efficacy data, and carry significant safety concerns. The FDA-approved dosing for letrozole (2.5 mg daily) and anastrozole (1 mg daily) applies exclusively to postmenopausal women with breast cancer 1, 2.

Why This Use Is Problematic

Lack of FDA Approval and Guideline Support

• No established indication exists for aromatase inhibitors in pediatric height augmentation
• All guidelines referencing these medications address breast cancer risk reduction or treatment in postmenopausal women 2, 3
• The only guideline mentioning aromatase inhibitors for height lists this as a research recommendation only, not an established practice 4

Limited and Disappointing Efficacy Data

The most recent and highest-quality evidence shows minimal benefit:

The 2024 Stanford randomized trial 5 demonstrated:

• Letrozole 2.5 mg daily vs anastrozole 1 mg daily for up to 3 years in 79 pubertal boys
• Predicted adult height gain was only +1.3 cm after 3 years (P = 0.043)
• No significant difference between letrozole and anastrozole groups
• The authors concluded: "The efficacy of AI as monotherapy for height augmentation in pubertal boys with idiopathic short stature may be limited, and safety remains an issue" 5

This directly contradicts earlier optimistic reports and represents the strongest evidence available.

Significant Safety Concerns

Common adverse effects documented across studies include:

• Metabolic disturbances: Elevated uric acid (63.9%), decreased HDL cholesterol (51.9%) 6
• Musculoskeletal issues: Severe acne (25.9%), knee pain (11.1%), fractures (4.6%) 6
• Behavioral changes: Excitement, hyperactivity, irritability, or conversely inactivity and drowsiness (1.9%) 6
• Organ dysfunction: Mild renal dysfunction (2.8%), abnormal liver function (1.9%) 6
• Bone health: Significant bone mineral density decreases documented in adult studies 1

The Evidence Landscape

While some Chinese studies suggest modest benefits when combining aromatase inhibitors with growth hormone 7, 6, 8, 9, these findings must be interpreted cautiously:

• Most positive studies combined AIs with growth hormone, making it impossible to isolate the AI effect
• The 2024 head-to-head comparison 5 represents the highest quality evidence and shows minimal benefit
• Ethnic differences may limit generalizability between populations 8
• Follow-up durations vary, with some studies showing early predicted height gains that don't persist 5, 10

Clinical Approach to Short Stature in Pubertal Boys

Instead of aromatase inhibitors, consider:

1. Evaluate for treatable causes of short stature:

   • Growth hormone deficiency (requires provocative testing if clinically indicated)
   • Hypothyroidism
   • Chronic kidney disease
   • Constitutional delay of growth and puberty

2. For confirmed growth hormone deficiency:

   • Recombinant human growth hormone at 0.045-0.05 mg/kg/day subcutaneously 4
   • This is FDA-approved and evidence-based

3. For constitutional delay:

   • Reassurance and monitoring may be appropriate
   • Short-term low-dose testosterone (50-100 mg IM) can be considered for psychological benefit without compromising final height

4. Avoid off-label aromatase inhibitor use given the unfavorable risk-benefit profile demonstrated in the most recent high-quality trial 5

Critical Pitfall

Do not extrapolate breast cancer dosing to pediatric height augmentation. The 2.5 mg letrozole and 1 mg anastrozole doses used in research studies were borrowed from oncology indications without pediatric pharmacokinetic or safety validation. The 2024 trial definitively shows this approach provides minimal benefit with concerning adverse effects 5.